Boehringer Ingelheim and AnGes have strengthened their long-standing collaboration with a new agreement focused on Boehringer Ingelheim AnGes HGF gene therapy. The partnership aims to accelerate the development and manufacturing of an innovative hepatocyte growth factor (HGF) gene therapy designed to treat peripheral arterial disease (PAD), a serious condition that affects more than 200 million people worldwide.
Under the agreement, Boehringer Ingelheim’s BioXcellence™ division will supply large-scale plasmid DNA manufacturing for the HGF gene therapy. AnGes has completed key clinical trials and is preparing to file a Biologics License Application (BLA) with the U.S. Food and Drug Administration. By combining AnGes’ clinical research expertise with Boehringer Ingelheim’s global biomanufacturing capabilities, the companies are advancing regulatory progress and supporting patients in need of new treatment options.
Boehringer Ingelheim and AnGes Advance HGF Gene Therapy
The agreement builds on nearly two decades of collaboration between the two companies. Boehringer Ingelheim’s microbial biologics facility in Vienna, Austria, has been central to producing high-quality plasmid DNA to support AnGes’ research and development programmes. This next phase extends that relationship, moving towards commercial-scale production and market readiness.
Targeting Peripheral Arterial Disease
PAD is a widespread circulatory condition that reduces blood flow to the limbs and is associated with serious complications, including limb amputation. The investigational HGF gene therapy developed by AnGes aims to stimulate new blood vessel formation, restoring blood flow and improving tissue recovery. Boehringer Ingelheim’s manufacturing support will be crucial in ensuring quality and availability as the therapy progresses through regulatory review.
Commitment to Collaboration
This collaboration reflects both companies’ commitment to delivering breakthrough therapies that address unmet medical needs. With Boehringer Ingelheim’s experience in microbial-based CDMO services and AnGes’ gene therapy expertise, the partnership demonstrates the value of long-term scientific alliances in accelerating innovation for patients worldwide.
